1000 Cures, Inc

Accelerating family-founded companies (FAMCOs) toward parent-powered cures for rare pediatric diseases

[1000 Cures, Inc @1000cures]

1000 Cures is the first accelerator built for FAMCOs:

family-founded biotech companies led by rare disease parents

[Ethan Perlstein 1-to-N @eperlste]

Why aren’t more people are talking about the Priority Review Voucher (PRV) program?

Folks act like it’s some kind of state secret.

It’s just a market exclusivity fee on global blockbusters that is paid by Big Pharma.

More accurately, it’s a consensual and democraticizing wealth transfer from Big Pharma to Baby Biotech aka FAMCOs.

One easy way to restore people’s trust in Pharma is for there to be more FAMCOs, or family-founded biotech companies, in the ecosystem.

So why aren’t we shouting PRV from the rooftops?

Are folks worried about an oversupply of PRVs that would crash the price?

@1000cures is taking the other side of that bet.

We believe that more PRVs will stimulate innovation by incentivizing competition for market share of global blockbuster medicines.

Big Pharma is vigorously competing to score approval on the next Ozempic and will happily fork over $200M+ for a chance at billions in sales.

It’s like buying a dollar for a dime.

And with longevity medicines on the horizon, the demand for market exclusivity on global blockbuster medicines will keep increasing.

[PRV Watch @PRVWatch]

Recently launched the new PRV Watch website tracking the world of FDA Priority Review Vouchers. Check it out: https://t.co/p1HlZY1FVM

[1000 Cures, Inc @1000cures]

1000 Cures is the first accelerator built for FAMCOs:

family-founded biotech companies led by rare disease parents

[1000 Cures, Inc @1000cures]

https://t.co/BG0YmLc8Zz is now live.

We welcome conversations with those who want to back the most determined founders in drug development — parents of children with rare pediatric diseases.

We’re witnessing one of the most compelling, yet under-recognized, shifts in biotech.

Parents of children with rare pediatric diseases are founding companies (FAMCOs) and operating with unmatched urgency and conviction. While traditional pharma often steps away due to small markets, these parent-founders are committing significant capital and time to develop real cures.

1000 Cures is the accelerator built for them.

We provide capital, infrastructure, regulatory expertise, and operational support to help these highly motivated operators move faster toward FDA-approved therapies — with a model anchored in the renewed Rare Pediatric Disease Priority Review Voucher (PRV) program.

This creates a powerful alignment of incentives: mission-driven execution with a clear, high-value monetization path. The result? A scalable platform with strong de-risking characteristics in one of biotech’s largest unmet needs — rare pediatric diseases, where >90% of conditions still have no approved treatment.

[1000 Cures, Inc @1000cures]

Many people in traditional pharma and biotech have never heard of “parent-founders.”

When a child is diagnosed with a rare pediatric disease, many parents don’t wait for someone else to act. They found their own companies — FAMCOs (family-founded companies) — with one singular mission: develop a cure for their child and others like them. These FAMCOs are operating at the same intensity and scientific rigor as traditional biotech teams… yet they’ve largely flown under the radar.

Why? Because many ultra rare diseases have such small patient markets that traditonal pharma sees little economic incentive to invest. Over 90% of rare diseases still have no FDA-approved treatment.

At @1000cures, we’re working to change that.
We exist to break down the systemic barriers these parent-founders face and provide them the capital, infrastructure, and operational support they need to succeed.

It’s time to shine a light on this powerful, under-recognized force in drug development — and accelerate the cures their children deserve.

If you’re a parent-founder, investor, or anyone working in rare disease, we’d love to connect!

[Ryan Ponzi @ryan_1000cures]

Step 1: Accelerate parent-powered cures for rare pediatric diseases
Step 2: Obtain PRV(s)
Step 3: Sell PRVs to pharma companies who believe they have the next “hot” consumer-based drug in the pipeline.

This is @1000cures

[1000 Cures, Inc @1000cures]

1000 Cures

Accelerating parent-powered cures for rare pediatric diseases one family, one program, one cure at a time.

What is 1000 Cures?
First accelerator purpose-built for rare disease family founders, the most motivated operators in biopharma.

How does it work?
Resourcing lean startups to reach FDA approval on capital efficient, expedited timelines compared to industry average.

Why now?
To end pediatric rare disease and secure priority review vouchers, which typically sell for 100M – 200M USD.